Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App




FDA Approves Molecular Diagnostics Platform for Smaller Labs

By LabMedica International staff writers
Posted on 25 Jul 2016
A latest-generation molecular diagnostics platform due to be released to the clinical laboratory market in the near future has already been cleared for use by the [U.S.] Food and Drug Administration (FDA).

The Luminex Corporation (Austin, TX, USA) has announced the receipt of FDA clearance (510k) for the company's new ARIES M1 System. More...
Having been designed for lower throughput clinical labs, the ARIES M1 System is a fully integrated, sample to answer platform for performing real-time PCR assays.

The ARIES system utilizes the Luminex proprietary MultiCode real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies. MultiCode products, which are used for the early detection of infectious diseases and genetic-based conditions, are centered on the unique MultiCode bases, isoC and isoG. The synthetic isoC:isoG DNA base pair differs from the naturally occurring base pair in its hydrogen bonding pattern. As a result, the MultiCode bases, isoC and isoG, can only base pair with each other. This property enables site-specific incorporation of the isobases during amplification. The isoC and isoG MultiCode bases form the building blocks for Luminex’s next generation MultiCode assays for nucleic acid-based testing.

The ARIES instrument uses internal barcode scanning and other advanced features to minimize operator errors. Two independent modules each support from one to six cassettes, allowing for both STAT and batch testing. An integrated touch screen PC eliminates the need for a separate computer, stand-alone keyboard, and mouse; thus maximizing valuable bench space. The low throughput ARIES M1 System provides one module with the ability to run one to six different assays according to the ARIES Universal Assay Protocol.

"In developing the ARIES family of systems, we listened closely to the needs of our customers and crafted these products to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today's lean laboratory. We are now adding another system based on customer feedback, and in doing so, expanding our market reach," said Homi Shamir, president and CEO of Luminex. "Luminex now has the broadest offering of low-plex and high-plex sample to answer systems for clinical laboratories performing molecular diagnostic testing. And, with the acquisition of NSPH behind us, we can focus on continuing to move products in our pipeline towards commercialization and realizing the value in our newly acquired asset."

The new diagnostics system will be on display at the July 31-August 4, 2016, Annual Scientific Meeting & Clinical Lab Expo of the American Association for Clinical Chemistry in Philadelphia, PA, USA.

Related Links:
Luminex



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.